Lupin on Monday said the US Food and Drug Administration (USFDA) has completed inspection of its Nagpur facility without making any observations. Lupin said its Nagpur facility manufactures oral solid products. Shares of Lupin edged up 0.23 per cent to close at ₹754.20 on the NSE; during intra-day deals, they rose to a high of ₹777.
Company news: Lupin
Published on
May 14, 2018 17:08
Tags